Real-World Experience of Safety of Mycophenolate Mofetil in 119 Japanese Patients with Systemic Lupus Erythematosus: A Retrospective Single-Center Study
Table 1
Characteristics of patients in the AE and no-AE groups.
Overall
No-AE group
AE group
value
Age at start of MMF therapy, median (IQR)
38 (31–46)
39 (31–46)
33 (29–45)
0.20
Female sex, (%)
101 (85)
74 (82)
27 (93)
0.23
Body weight (kg), median (IQR)
55 (48–63)
57 (48–64)
54 (46–62)
0.23
Duration of SLE, months, median (IQR)
138 (39–242)
133 (40–227)
160 (23–262)
0.68
MMF started as induction therapy, (%)
96 (81)
72 (81)
24 (83)
1.00
Malar rash, (%)
62 (52)
51 (57)
11 (38)
0.09
Discoid rash, (%)
23 (20)
16 (18)
7 (24)
0.59
Photosensitivity, (%)
31 (26)
21 (24)
10 (35)
0.15
Oral ulcers, (%)
31 (27)
20 (23)
11 (38)
0.33
Arthritis, (%)
75 (64)
54 (61)
21 (72)
0.28
Serositis, (%)
28 (24)
23 (26)
5 (17)
0.45
Renal disorder, (%)
81 (68)
62 (69)
19 (66)
0.82
Neurologic disorder, (%)
9 (8)
6 (7)
3 (10)
0.69
Hematologic disorder, (%)
89 (75)
68 (76)
21 (72)
0.8
Immunologic disorder, (%)
118 (99)
89 (99)
29 (100)
1.00
Antinuclear antibody, (%)
119 (100)
90 (100)
29 (100)
N/A
SLEDAI at start of MMF therapy, median (IQR)
6 (4–10)
6 (4–10)
8 (4–13)
0.14
Number of SLE flare-ups, median (IQR)
1 (1–3)
2 (1–2)
1 (0–3)
0.30
WBC count (/μL), median (IQR)
6,600 (4,500–7,900)
6,100 (4,400–7,600)
7,000 (5,800–9,500)
0.07
Lymphocytes (/μL), median (IQR)
1,001 (598–1,335)
925 (544–1,326)
1,039 (619–1,404)
0.41
Hemoglobin (g/dL), median (IQR)
11.8 (10.6–13.1)
12.1 (11.1–13.2)
11.2 (10–12.3)
0.014
Platelets (104/μL), median (IQR)
23.3 (18.6–28.8)
23.6 (19.3–28)
22.4 (17.8–30.7)
0.91
AST (U/L), median (IQR)
19 (15–24)
18 (15–24)
19 (15–25)
0.67
ALT (U/L), median (IQR)
18 (12–28)
16 (11–25)
25 (15–34)
0.011
Albumin (g/dL), median (IQR)
3.5 (3–3.9)
3.6 (3.1–3.9)
3.2 (2.6–3.8)
0.06
BUN (mg/dL), median (IQR)
15 (11–20)
14 (10–19)
18 (14–27)
0.006
Creatinine (mg/dL), median (IQR)
0.62 (0.49–0.83)
0.62 (0.49–0.78)
0.57 (0.48–0.99)
0.48
eGFR (mL/min/1.73 m2), median (IQR)
91 (67–115)
92 (70–115)
89 (46–124)
0.63
CH50 (U/mL), median (IQR)
28 (20–38)
29 (21–39)
25 (16–37)
0.33
C3 (mg/dL), median (IQR)
66 (48–84)
69 (52–85)
61 (44–83)
0.38
C4 (mg/dL), median (IQR)
11 (7–18)
12 (7–19)
10 (5–17)
0.31
IgG (mg/dL), median (IQR)
1,220 (914–1,455)
1,243 (943–1,431)
1,151 (597–1,718)
0.59
Anti-DNA antibody (RIA) (IU/mL), median (IQR)
11 (0–62)
7 (0–50)
30 (5–188)
0.053
Anti-U1-RNP antibody, positivity, (%)
43 (36)
34 (38)
9 (31)
0.52
Anti-Sm antibody, positivity, (%)
16 (14)
14 (16)
2 (7)
0.35
Anti-CL antibody, positivity, (%)
26 (22)
22 (25)
4 (14)
0.30
Anti-CLβ2GP1 antibody, positivity, (%)
13 (11)
9 (10)
4 (14)
1.00
Lupus anticoagulant, median (IQR)
0.9 (0.9–1)
1 (0.9–1)
0.9 (0.8–1)
0.51
Proteinuria (g/day), median (IQR)
0.6 (0–2.3)
0.5 (0–2.1)
0.7 (0–2.5)
0.46
Hematuria, positivity, (%)
38 (33)
28 (33)
10 (35)
1.00
GC dose at start of MMF therapy (mg/day), median (IQR)
